Zhitong Finance App News, Cansino Biotech (06185.HK) announced that the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/ tetanus toxoid) (PCV24) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials.

Zhitong Finance App News, Cansino Biotech (06185.HK) announced that the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/ tetanus toxoid) (PCV24) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials.